ADDISON, Texas, Sept. 30, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR), today announced the expansion of the Altrazeal® international marketing network to include Scandinavia and Finland.
Marketing and distribution agreements have been signed with companies with extensive wound care experience to exclusively distribute Altrazeal® in these territories. It is anticipated that the initial product shipment will be made in the fourth quarter 2013.
Commenting on the extension of the international marketing network, Helmut Kerschbaumer, Managing Director of Altrazeal GmbH, stated, "This represents a continuation of our strategy of appointing highly qualified companies throughout the territory to exclusively market and distribute Altrazeal®. Significant activities have already been completed within the Scandinavian and Finnish markets including extensive training of company representatives and opinion leaders. I am very confident that our outstanding partners will successfully establish Altrazeal® as a leading product in these markets."
Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing. Altrazeal® competes in the advanced wound dressing market which, worldwide, is estimated to be $6.5 billion growing annually at 13%. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous leg ulcers and geriatric wounds.
Commenting on the expansion of the international marketing network, Kerry P. Gray, President and CEO of ULURU, stated, "We are very pleased with the progress Altrazeal GmbH has made securing experienced marketing partners throughout the territory. The interest companies have expressed, throughout the territory, to marketing Altrazeal® clearly validates the market potential of Altrazeal®, a cost effective alternative in the advanced wound care market."
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.ULURUinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the launch of Altrazeal® in the territory, the commercial potential of Altrazeal®, the interest of companies throughout the territory and the demonstration of cost savings and clinical benefits, and the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by us with the Securities and Exchange Commission.
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
SOURCE ULURU Inc.